HGH (Somatropin)
FDA ApprovedHuman Growth Hormone | Somatropin
Community Research
Join others researching HGH — share findings, ask questions, and learn from real experiences
Human Growth Hormone (HGH/Somatropin) is a 191-amino acid polypeptide hormone FDA-approved for pediatric and adult growth hormone deficiency, HIV-associated wasting, and other conditions. It provides both direct and indirect (IGF-1 mediated) anabolic effects.
Binds to GH receptors on target tissues, triggering JAK2-STAT5 signaling pathway. Direct effects include lipolysis, protein synthesis, and metabolic regulation. Indirect effects via IGF-1 promote growth and anabolism. Half-life ~3 hours subcutaneously.
Molecular Data
Research Indications
FDA-approved for idiopathic and organic causes, Turner syndrome, Prader-Willi syndrome, SGA, Noonan syndrome, SHOX deficiency.
FDA-approved for childhood-onset or adult-onset causes (pituitary tumors, surgery, radiation, trauma).
FDA-approved to increase lean body mass and body weight in cachexia.
Significant fat loss especially abdominal/visceral fat over 1-3 months.
Increased muscle mass and improved body composition.
Enhanced exercise recovery and tissue healing.
Improved skin elasticity, texture, and hair/nail growth.
Improved energy, sleep, and quality of life.
Dosing Protocols
Subcutaneous injection is the only effective route. Morning fasted injection maximizes fat-burning potential; evening mimics natural nocturnal GH pulse.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Medical GHD (Starting) | 0.15-0.3mg/day (0.5-1 IU) | Once daily | SubQ |
| Medical GHD (Maintenance) | 0.4-0.8mg/day (1.2-2.4 IU) | Once daily | SubQ |
| Anti-Aging/Wellness | 1-2 IU/day (0.33-0.67mg) | Once daily | SubQ |
| Body Recomposition | 2-4 IU/day (0.67-1.33mg) | Once or twice daily | SubQ |
| Performance (Higher Risk) | 4-8 IU/day (1.33-2.67mg) | Split twice daily | SubQ |
Reconstitution Instructions
- HGH lyophilized powder vial (typically 10 IU or 36 IU)
- Bacteriostatic water for injection
- Insulin syringes (29-31 gauge)
- Alcohol prep pads
- 1 Allow vial to reach room temperature (15-20 minutes)
- 2 Clean rubber stoppers with alcohol swab
- 3 Determine reconstitution volume (typical: 1mL BAC water per 10 IU)
- 4 Draw bacteriostatic water slowly, removing air bubbles
- 5 Insert needle at angle, aiming stream at vial wall - not directly on powder
- 6 Inject water slowly down inside wall, drop by drop
- 7 Remove needle and gently swirl in circular motion - never shake
- 8 Allow to sit if cloudy, then swirl again until crystal clear
- 9 Solution must be crystal clear; discard if cloudy or contains particles
- 10 Label with reconstitution date and concentration
- 11 Store refrigerated at 2-8°C; use within 14-28 days
Interactions
What to Expect
Side Effects & Safety
Common Side Effects
- Water retention and fluid accumulation
- Joint pain and stiffness
- Carpal tunnel syndrome (usually resolves with dose reduction)
- Headaches
- Numbness/tingling in hands
Stop Signs - Discontinue if:
- Severe or worsening carpal tunnel symptoms
- Signs of diabetes (increased thirst, frequent urination, blurred vision)
- Severe edema (facial, hand, or feet swelling)
- Severe joint/muscle pain unresponsive to dose reduction
- New lumps, masses, or rapidly growing moles
- Severe headaches or vision changes
- Signs of allergic reaction
- Gynecomastia (breast tissue growth in males)
- Hypothyroid symptoms (fatigue, weight gain, cold intolerance)
Contraindications
- Active cancer (may accelerate tumor growth)
- Acute critical illness (increased mortality in ICU patients)
- Closed epiphyses in children (for growth promotion)
- Pregnancy/breastfeeding
Quality Checklist
Good Signs
- White to off-white lyophilized powder or solid cake (not liquid/collapsed)
- Crystal clear reconstituted solution with no particles
- Intact vacuum in sealed vial (resistance when inserting needle)
- Pharmaceutical grade with certificate of analysis (Genotropin, Norditropin, Humatrope preferred)
Warning Signs
- Generic/underground lab products have highly variable quality and potency
- Common counterfeits exist; third-party testing recommended
Bad Signs
- Cloudy, discolored, or particles visible indicates degradation
- Powder appears melted or stuck to vial (improper storage)
- Yellow/brown coloring
References
- Long-term Safety of Growth Hormone in Adults With Growth Hormone Deficiency: Overview of 15,809 GH-Treated PatientsStochholm K, Kiess W, Gianetti E, et al.Journal of Clinical Endocrinology & Metabolism (2022)
15,809 patients from the KIMS database, mean 5.3 years follow-up. Adverse events in 51.2% of patients, treatment-related in 18.8%. No correlation between GH dose and adverse event rate. Supports long-term safety of GH replacement in adults with GHD.
- Efficacy and Safety of Growth Hormone Treatment in Adults with Growth Hormone Deficiency: A Systematic Review of Studies on MorbidityDefined a, Sääf M, et al.Clinical Endocrinology (2014)
Systematic review demonstrating positive effects of GH treatment on cardiovascular disease and fracture risk, improvements in body composition, muscle strength, quality of life, bone mass/density, and lipoprotein patterns.
- Cardiovascular Risk in Growth Hormone Deficiency: Beneficial Effects of Growth Hormone Replacement TherapyGazzaruso C, Gola M, Karamouzis I, et al.Endocrine (2016)
GH deficiency is associated with several cardiovascular risk factors that significantly increase cardiovascular morbidity and mortality. GH replacement improves cardiovascular risk factors.
- Unmasking of Central Hypothyroidism Following Growth Hormone Replacement in Adult Hypopituitary PatientsAgha A, Walker D, Perry L, et al.Clinical Endocrinology (2007)
In 84 apparently euthyroid patients, 30 (36%) developed hypothyroidism requiring T4 therapy after starting GH. Highest risk in patients with organic pituitary disease or multiple pituitary hormone deficiencies.
Related Peptides
Disclaimer
This information is for educational and research purposes only. Consult a healthcare professional before use.